Isosceles Pharmaceuticals Signs Non-Binding Letter of Intent With a Strategic Partner for Phase 1 Development of Its Proprietary Synthetic Cannabidiol Intravenous Product
- Monday, October 31, 2022, 7:46
- Finance
- Add a comment
WILMINGTON, N.C., Oct. 31, 2022 /PRNewswire/ — Isosceles Pharmaceuticals, Inc., a preclinical stage pharmaceutical company (“Isosceles”, or the “Company”) engaged in the development of synthetic cannabidiol for the treatment of pain has announced the execution of a non-binding letter of…
About the Author
adminasapcorp has written 37652 stories on this site.